• <em>NTRK</em> Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients
• A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
• A narrative review of methods for the identification of <em>ALK</em> fusions in patients with non-small cell lung carcinoma
• A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With <em>ALK</em>-Positive NSCLC in Japan
• A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
• A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
• Advancements of ALK inhibition of non-small cell lung cancer: a literature review
• AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
• Alectinib for treating patients with metastatic <em>ALK</em>-positive NSCLC: systematic review and network metanalysis
• Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion
• Alectinib-induced rash unresponsive to desensitization: a case report and literature review
• ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
• ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression
• ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
• ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report
• An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
• Anaplastic lymphoma associated with breast implants-Early diagnosis and treatment
• Applying computer text mining algorithms for oversampling tumor mutation status in medical records for the NCI Patterns of Care studies
• Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced <em>ALK</em>-Positive NSCLC
• Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
• Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
• Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma
• Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial
• Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
• Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
• Case report: anaplastic lymphoma kinase (<em>ALK</em>) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
• Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with <em>LDLR-ROS1</em> fusion
• Charge Transfer Complex of Lorlatinib with Chloranilic Acid: Characterization and Application to the Development of a Novel 96-Microwell Spectrophotometric Assay with High Throughput
• Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review
• Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
• Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
• Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis
• Comparing Fractionated and Single-Fraction Gamma Knife Radiosurgery for Brain Metastases From Non-Small-Cell Lung Cancer With a Focus on Driver Alterations
• Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE)
• Constant small-cell changes and variable LEF1 expression in DUSP22-rearranged primary cutaneous anaplastic large-cell lymphoma: Analysis of the repeated biopsies of three patients
• Corrigendum to 'Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study' Cancer Genetics 270-271 (2022) 32-38
• Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
• Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells
• Cytological examination of peripheral blood cell block to diagnose small cell variant ALK-positive anaplastic large cell lymphoma
• Cytological features of oral malignant lymphoma in scraping liquid-based cytology: Cases of plasmablastic lymphoma and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
• Desmoid-type fibromatosis of the mesentery: a clinicopatho-logical and genetic analysis of 9 cases
• Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
• Discovery of a miniaturized PROTAC with potent activity and high selectivity
• Discovery of imidazo[1,2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants
• Distinct metastatic spread and progression patterns in patients treated with crizotinib for <em>ROS1</em>- and <em>ALK</em>-rearranged non-small cell lung cancer: a single-center retrospective study
• Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
• Early Onset Pulmonary Events and Management Strategies during the Treatment of 
ALK Positive NSCLC Patients with Brigatinib
• EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries
• Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
• Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
• External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
• First-Line Alectinib vs. Brigatinib in Advanced NSCLC with ALK Rearrangement: Real-World Data
• Gastrointestinal ALK-positive anaplastic large cell lymphoma: a clinicopathological analysis of five cases
• Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases
• Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer
• Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique
• Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer
• Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults
• Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy
• Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial
• Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
• Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer
• Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
• LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
• Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
• Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method
• Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
• Metabolic protein kinase signalling in neuroblastoma
• MiR-146a-5p enrichment in small-extracellular vesicles of relapsed pediatric ALCL patients promotes macrophages infiltration and differentiation
• New perspectives for targeting therapy in ALK-positive human cancers
• Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report
• Novel High-Throughput Microwell Spectrophotometric Assay for One-Step Determination of Lorlatinib, a Novel Potent Drug for the Treatment of Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer
• Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
• Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report
• Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer
• Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib
• Patient-led advocacy in ALK-positive lung cancer
• Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer
• Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
• Pre-clinical modelling of ROS1+ non-small cell lung cancer
• Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates
• Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021
• Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy
• Remarkable Clinical Response of <em>ALK</em>-Rearranged/<em>TP53</em>-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
• Research Progress in the Efficacy and Safety of ALK Inhibitors 
in the Treatment of NSCLC Brain Metastasis
• Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer
• Safety and efficacy of alectinib versus crizotinib in alk-positive non-small cell lung cancer: An update meta-analysis
• Solitary Extramedullary Plasmacytoma With Development of T-cell Anaplastic Large-Cell Lymphoma: A Rare Case Report and Literature Review
• Successful treatment of small cell variant anaplastic large cell lymphoma with allogeneic peripheral blood stem cell transplantation, and review of the literature
• Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements
• Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
• Targeted therapy for lung cancer: Beyond EGFR and ALK
• Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma
• Targeting gene fusions in non-small cell lung cancer-a ceaseless success story?
• TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
• Textured versus Smooth Tissue Expanders: a Comparison of Complications in 3,526 Breast Reconstructions
• The Efficacy of PCSK9 Inhibitors in Treating Hypercholesterolemia Caused by Lorlatinib: A Report of Two Cases
• The molecular characteristics of non-small cell lung cancer in the Northern Territory's Top End
• ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells